Antibiotic Treatment for Hidradenitis Suppurativa
For mild-to-moderate HS, start with tetracyclines (doxycycline 100mg twice daily or tetracycline 500mg twice daily) for a 12-week course; for moderate-to-severe disease, use combination clindamycin 300mg plus rifampin 300mg twice daily as first-line systemic therapy. 1
Disease Severity-Based Antibiotic Selection
Mild-to-Moderate Disease (Hurley Stage I-II)
Tetracyclines are the recommended first-line oral antibiotics with Level I evidence supporting their use for 12-week courses or as long-term maintenance therapy when appropriate 1. The 2019 North American guidelines specifically endorse this approach based on an RCT showing 30% reduction in abscesses 1. While doxycycline 100mg twice daily is most commonly prescribed in practice, tetracycline 500mg twice daily is equally effective 1.
For very mild disease limited to pustules, topical clindamycin 1% solution may be considered, though it carries significant limitations: it reduces pustules but has no effect on inflammatory nodules or abscesses, and critically increases Staphylococcus aureus resistance rates 1. If using topical clindamycin, combine with benzoyl peroxide to reduce resistance risk 1.
Moderate-to-Severe Disease (Hurley Stage II-III)
The combination of clindamycin 300mg plus rifampin 300mg, both twice daily, is recommended as second-line treatment for mild-to-moderate disease or as first-line/adjunct treatment in severe disease 1. This combination has the most robust evidence among antibiotic regimens in HS, supported by systematic reviews 1. The guideline explicitly states this is effective as second-line therapy, making it the logical escalation when tetracyclines fail 1.
Refractory or Severe Disease
For second- or third-line treatment in moderate-to-severe disease that has failed standard antibiotics, use the triple combination of moxifloxacin, metronidazole, and rifampin 1. This regimen is specifically recommended by the North American guidelines for more resistant cases.
Intravenous ertapenem is recommended for severe disease as a one-time rescue therapy or as a bridge to surgery or other long-term maintenance 1. This is typically administered for 4-6 weeks with an average remission period of 1-3 months 2. The most common indications are severe disease and biologic treatment failure 2.
Critical Treatment Principles
Duration and Monitoring
- Standard antibiotic courses should be 12 weeks minimum 1
- Long-term maintenance therapy is appropriate when patients respond well 1
- Recurrence following cessation is frequent, so balance benefit against antibiotic resistance risk 1
- Consider transitioning responders to biologics (adalimumab) or surgery for definitive control rather than indefinite antibiotics
Common Pitfalls to Avoid
Do not use topical clindamycin monotherapy for anything beyond mild pustular disease - it will not address nodules or abscesses 1
Do not use rifampin as monotherapy - it should always be combined with clindamycin to prevent resistance 1
Avoid progestogen-only contraceptives in female patients - anecdotal data suggest these may worsen HS 1
Recognize that antibiotics alone are insufficient in advanced disease - their role becomes adjunctive, and surgery or biologics become necessary 1
Adjunctive Measures
While on antibiotics, patients should use:
- Antibacterial washes (chlorhexidine, zinc pyrithione, or benzoyl peroxide) 1
- Intralesional triamcinolone 10mg/mL for acute inflamed lesions (provides rapid pain relief within 1 day) 1
When Antibiotics Are Not Enough
The guidelines emphasize that in advanced disease, antibiotics serve an adjunctive role due to lower response rates and increased recurrence 1. At this stage, transition to adalimumab (the only FDA-approved biologic for HS with Level I evidence) or consider surgical intervention 1. The strongest evidence supports combining medical therapy with surgery for optimal outcomes in moderate-to-severe disease 3.